Li Mingguang, Reineke Joshua
Optimum Therapeutics, LLC, San Diego, CA, USA.
Methods Mol Biol. 2012;926:369-82. doi: 10.1007/978-1-62703-002-1_24.
This chapter introduces the principles and development procedures for physiologically based pharmacokinetic (PBPK) models, and their application for nanoparticle toxicity studies. PBPK models describe the concentration-time or mass-time profiles of chemicals or nanoparticles in individual tissues and organs within the body. They have been used mostly for toxicology and pharmacology studies of small molecules, and their application for nanoparticles are in the early stages. Due to the biodistribution differences between nanoparticles and small molecules, modification may be necessary to build PBPK models for nanoparticles. PBPK models for nanoparticles may be applied to biodistribution predictions, data extrapolation, and property-biodistribution relationships, and, thus, can be a powerful tool in toxicity evaluation.
本章介绍了基于生理的药代动力学(PBPK)模型的原理和开发程序,以及它们在纳米颗粒毒性研究中的应用。PBPK模型描述了体内各个组织和器官中化学物质或纳米颗粒的浓度-时间或质量-时间曲线。它们主要用于小分子的毒理学和药理学研究,而其在纳米颗粒方面的应用尚处于早期阶段。由于纳米颗粒和小分子在生物分布上存在差异,可能需要进行修改才能构建纳米颗粒的PBPK模型。纳米颗粒的PBPK模型可应用于生物分布预测、数据外推以及性质-生物分布关系,因此,可成为毒性评估的有力工具。